Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-dense Temozolomide Followed by Bevacizumab vs Bevacizumab Alone in Recurrent Glioblastoma
NCT02761070Phase 3Completed
- Sponsor
- Kyorin University
- Start
- Jul 2016
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of temozolomide in glioblastoma (GBM) (2 arms), sponsored by Kyorin University. Primary endpoint: Overall Survival up to 2 years. Started Jul 2016; status: completed.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02761070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02761070.